Big buy

Srinivas Akkaraju: large open-market buy of KLRS

$5M open-market purchase by Srinivas Akkaraju, Director at Kalaris Therapeutics,Inc., filed February 18, 2026. Learn more

Feed status Last SEC check:Loading Last Filing: Loading
View KLRS
Access Free feed
Quick read What does this view show?

What this is

Single filing record

This page shows the rows from one Form 4 filing as reported to the SEC.

Why it matters

Read the SEC filing

The original SEC document is the source record. Always verify before drawing conclusions.

How to read it

Role, size, timing

Insider activity carries more weight from senior officers, large dollar values, and clustered timing.

Big BuyKLRS
$4.72+1.51% today

Srinivas Akkaraju · Director at Kalaris Therapeutics,Inc.

$5M

Srinivas Akkaraju bought $5M of KLRS (Kalaris Therapeutics,Inc.).

Filed February 18, 2026

Filings

Recent insider trades

Status Loading

Loading public insider data...

Latest visible filing loading.

Public Form 4 filings, normalized for cleaner scanning. What do these codes mean?

TickerType & RoleValue

View all KLRS insider activity →

Share

Share this story

Srinivas Akkaraju bought $5M of KLRS. Large open-market insider purchase reported on SEC Form 4.

Weekly recap

Get the easier version in your inbox.

Start with the free weekly recap. Upgrade later if you want the paid daily brief.

Free weekly recap. No login required. Unsubscribe any time.

Method Public Form 4 filings, normalized for cleaner scanning. Filtered rows stay available in All Form 4 Filings and ticker history. Which view should I use? →